Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04557956
Title Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Tazemetostat

Dabrafenib + Tazemetostat + Trametinib

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Emory University Hospital/Winship Cancer Institute Recruiting Atlanta Georgia 30322 United States Details
Northwestern University Recruiting Chicago Illinois 60611 United States Details
Siteman Cancer Center at West County Hospital Recruiting Creve Coeur Missouri 63141 United States Details
Washington University School of Medicine Recruiting Saint Louis Missouri 63110 United States Details
University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh Pennsylvania 15232 United States Details
Huntsman Cancer Institute/University of Utah Recruiting Salt Lake City Utah 84112 United States Details
University of Wisconsin Carbone Cancer Center Recruiting Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field